Related Experiment Video
Updated: Jul 10, 2025
Synovial Fluid Analysis to Identify Osteoarthritis
Published on: October 20, 2022
Synovial biopsies for molecular definition of rheumatoid arthritis and treatment response phenotyping: where can we
Francesco Salvatore Iaquinta1, Felice Rivellese1, Costantino Pitzalis1,2
1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust & National Institute for Health and Care Research (NIHR) Barts Biomedical Research Centre (BRC), London, UK.
Introduction:
The extensive knowledge gained in the cellular and molecular mechanisms underlying Rheumatoid Arthritis (RA) pathogenesis has led to therapeutic advances. However, up to 10-20% of patients fail to respond to multiple therapeutic agents being classified as multi-drugresistant. A key challenge moving forward will be the implementation of synovial biopsies in clinical practice to facilitate the shift from the current trial-and-error strategy toward new forms of clinical trials. Biomarker-driven trials have the potential to improve drug selection and patient stratification, reduce economic costs and unnecessary drug-related toxicity.
Areas Covered:
This special report explores the clinical and research applications of synovial biopsy, the advancement in the molecular pathobiology of RA to better understand disease pathogenesis and treatment response, and the way forward for the paradigm shift needed.
Expert Opinion:
In the current era of highly targeted biologic drugs which have dramatically transformed the outlook of RA patients, the use of synovial biopsy represents a valuable practical tool to dissect disease pathogenesis and, consequently, treatment response. In the near future, it is hoped that technological advances will allow for speeding up synovial molecular analysis and that the design of new biomarker-driven trials will enable the allocation of patients to more effective treatment.
Insights
Synovial biopsies can improve Rheumatoid Arthritis (RA) treatment by enabling biomarker-driven trials. This approach moves beyond trial-and-error to personalize drug selection and reduce patient toxicity.
Area of Science:
- Rheumatology
- Molecular Biology
- Clinical Research
Background:
- Rheumatoid Arthritis (RA) pathogenesis knowledge has advanced therapies.
- 10-20% of RA patients exhibit multi-drug resistance, failing multiple treatments.
- Current treatment selection often relies on a trial-and-error approach.
Purpose of the Study:
- To explore clinical and research applications of synovial biopsy in RA.
- To discuss advancements in RA molecular pathobiology for understanding pathogenesis and treatment response.
- To outline a paradigm shift towards personalized medicine in RA treatment.
Main Methods:
- Review of current literature on synovial biopsy applications.
- Analysis of molecular pathobiology advancements in RA.
- Discussion of clinical trial design incorporating biomarkers.
Main Results:
- Synovial biopsy is a valuable tool for dissecting RA pathogenesis and treatment response.
- Biomarker-driven trials can improve drug selection and patient stratification.
- Technological advances are expected to expedite synovial molecular analysis.
Conclusions:
- Implementation of synovial biopsies in clinical practice is crucial for advancing RA treatment.
- Biomarker-driven trials offer a path to more effective and personalized RA therapy.
- Personalized treatment strategies can reduce economic costs and drug-related toxicity in RA patients.
